Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Accumulated Depreciation & Amortization (2016 - 2026)

Myriad Genetics has reported Accumulated Depreciation & Amortization over the past 16 years, most recently at $87.9 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 19.8% to $87.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $87.9 million through Dec 2025, down 19.8% year-over-year, with the annual reading at $87.9 million for FY2025, 19.8% down from the prior year.
  • Accumulated Depreciation & Amortization was $87.9 million for Q4 2025 at Myriad Genetics, up from $83.3 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $119.9 million in Q4 2023 and troughed at $79.4 million in Q2 2025.
  • The 5-year median for Accumulated Depreciation & Amortization is $108.8 million (2022), against an average of $105.2 million.
  • Year-over-year, Accumulated Depreciation & Amortization grew 9.8% in 2023 and then plummeted 31.02% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $106.9 million in 2021, then grew by 2.15% to $109.2 million in 2022, then increased by 9.8% to $119.9 million in 2023, then decreased by 8.59% to $109.6 million in 2024, then fell by 19.8% to $87.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Accumulated Depreciation & Amortization are $87.9 million (Q4 2025), $83.3 million (Q3 2025), and $79.4 million (Q2 2025).